On 21 May 2026, Lilly announced positive topline results from TRIUMPH-1 (not yet peer-reviewed), the pivotal Phase 3 obesity trial
Resting-state functional connectivity in individuals with bipolar disorder during clinical remission: a systematic review
If glutathione IV doesnt seem right for you, or youre understandably wary of the needles and risks, you can consider alternatives
Does the type of food I eat after the window matter
Given the evidenced benefits of BPC-157 on neurological health, including neuroprotection, neurotransmitter modulation, and the maintenance of systemic homeostasis via the brain-gut axis, it may be particularly suited to nasal administration
Additional benefits of GLP-1 include the reduction of risk for adverse cardiovascular events in individuals with obesity and or Type 2 Diabetes due to its anti-inflammatory action